Activation of tyrosine kinases by mutation of the gatekeeper threonine - Test2 - elhamkhani - TriplyDB

Activation of tyrosine kinases by mutation of the gatekeeper threonine

Activation of tyrosine kinases by mutation of the gatekeeper threonine

http://www.wikidata.org/entity/Q27652166

about

Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles Selectivity and therapeutic inhibition of kinases: to be or not to be?Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs Ten things you should know about protein kinases: IUPHAR Review 14 Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Design principles underpinning the regulatory diversity of protein kinases Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 Chemical genetic strategy for targeting protein kinases based on covalent complementarity Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor Sequence Determinants of a Specific Inactive Protein Kinase Conformation Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology Directed evolution of Mycobacterium tuberculosis β-lactamase reveals gatekeeper residue that regulates antibiotic resistance and catalytic efficiency Staurosporine-Derived Inhibitors Broaden the Scope of Analog-Sensitive Kinase Technology Mechanisms of drug resistance in kinases.Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD Dynamics-Driven Allostery in Protein Kinases ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it Novel autophosphorylation sites of Src family kinases regulate kinase activity and SH2 domain-binding capacity Allosteric interactions between the myristate- and ATP-site of the Abl kinase Mutations in the catalytic loop HRD motif alter the activity and function of Drosophila Src64 Deciphering the structural basis of eukaryotic protein kinase regulation c-Src binds to the cancer drug Ruxolitinib with an active conformation The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics NMR Characterization of Information Flow and Allosteric Communities in the MAP Kinase p38γ Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop Protein kinases: evolution of dynamic regulatory proteins Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase.Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Protein-structure-guided discovery of functional mutations across 19 cancer types Conformational disturbance in Abl kinase upon mutation and deregulation.

P2860

Q24614202-4675F5A4-89EB-4DEB-BFFD-ADC0F7021FC7 Q24656006-D50A0BEE-E080-4337-B5AB-455E48D9ACCA Q26769659-9B4D06E0-DE20-454F-A093-3820968D282C Q26849417-0237F1AA-326D-46EE-AA0D-16F5A6A3B4BE Q27026323-90725B5C-F539-4972-80DE-C64267840A3E Q27027644-CA1DEB02-B8A6-4B70-9F47-5E332F6CC33B Q27654059-3D9BFDB0-6804-41A1-8443-618AA101518C Q27660281-D3582027-435F-4C16-8284-C16692F44B4B Q27667482-CFC9B264-7FB6-4020-BAEB-3CE28CCF2FB1 Q27671824-169DE230-F265-4F03-A803-45055CEC885F Q27677383-CFD6FB4F-55FF-474C-B93C-6DE50777F77A Q27678722-77577DCA-7C25-455D-863D-1D50E7C0A136 Q27679025-4D14CAB2-7DB8-431F-91F5-F6390E3447F8 Q27679915-E84ED601-F2C1-4A63-802E-80C586C8258E Q27680486-CF4580AB-A5B3-4E18-AC61-442E0D2E7431 Q27692567-C0DA63DE-BEA9-42D1-AA2D-9F91A3218BB4 Q27698001-0C41557C-D58A-4356-AD76-D604FA3976CE Q27727987-C4FB1392-2474-47C8-842F-B630BE24A1DB Q27852087-34C74BF9-EDC7-4EAE-9ACB-8E224847B235 Q28081279-2A7A39A8-9768-4FFF-9CF7-E8F8D2EE3058 Q28083386-BD36F1A4-8AFC-4A95-AC51-8D401B77BF1D Q28115874-1E9A0C94-54BD-4844-B058-038D68D8066A Q28476718-383D12EF-0A4C-4954-A1AA-DA5122CEDA53 Q28478151-D5B891BA-C76A-47B3-869F-63D208920BF6 Q28534399-482BAC18-3315-4CEF-B1DB-B640235E7488 Q28542851-210CCD0B-CA79-4803-A60D-B25A7259AD81 Q28543640-3C27D636-DA83-41E1-9D77-3ECFA2A2C1FE Q28548366-B9AD68B0-A4AC-4776-8217-35CCE9C11552 Q28551159-4898715D-1900-44ED-A0E6-5EECF1C84062 Q28828493-F1560A83-4268-4C28-977A-EA1E316B4673 Q30008882-3C4F8335-4795-4E1D-96F3-D87E39026558 Q30008916-2A0AD219-CA5B-43AB-B889-67108C94B7DB Q30009548-20A27B44-3942-414B-BEF5-07ED7DE1C2EB Q30014836-6D974A06-F9D6-4559-AC42-43E9059CAEF5 Q30157152-13BD2A44-D1FB-453C-B32F-A7B53A474BA9 Q30368961-1B41FFF3-F739-407E-B864-D633CEFA2F39 Q30372772-0D3FDCAF-B66E-4AA8-BB68-17DC1BC47CE4 Q30374671-D50AE02E-E10C-45B1-947C-38067E98F78A Q30389229-B8D0522D-CA38-419A-96EE-24B31E4DCD65 Q30485823-D0ACF931-31EA-462C-B236-305B7DBE4BC3

P2860

Activation of tyrosine kinases by mutation of the gatekeeper threonine

http://www.wikidata.org/entity/Q27652166

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@ast

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@en

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@nl

type

label

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@ast

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@en

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@nl

prefLabel

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@ast

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@en

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@nl

P1433

Q27652166-3843602D-1726-4378-980B-6F1A6F08AFA1

P1476

Q27652166-0A563D02-E1A5-4A18-A000-008B5DA3F7E0

P2093

Q27652166-3FCEF5BC-D079-4DD4-9042-857248C34F7D

Q27652166-C77F7ADE-1705-47FC-936D-29FC40FD5F37

P2860

Q27652166-001A2A7F-4ACB-4941-888C-05D61DE74F15

Q27652166-0250DEDD-67B6-4942-B195-E11C20439B9D

Q27652166-05013A5D-2CEE-4501-B0C8-FFE1B7A341B3

Q27652166-07138FA3-EED6-4578-B6D5-FFB46163CC5F

Q27652166-0E2575DB-2324-4767-B76B-15D2F621EA5E

Q27652166-123E3191-3B9B-4368-B5A1-A3B9F807405E

Q27652166-187CBC94-0135-44B9-88A9-70E4CFE00DFB

Q27652166-18CA3E72-AAE5-4F81-A112-A79B77B6C00C

Q27652166-2226AB71-C740-4F34-8257-F198932A6479

Q27652166-2227BEA2-9DD1-41BA-ACB9-23FC8269A960

P2888

Q27652166-CC8FE05D-6929-48A4-8906-DE52A752C778

P304

Q27652166-1084D3CF-E124-44E0-AB82-5990A4DBE0BD

P31

Q27652166-589907F8-4F7D-4CAF-ADD2-CAD519B682F4

P3181

Q27652166-94A1230F-F91B-4279-8C61-ADE89C4F01E2

P356

Q27652166-2FC20530-0081-444F-84E1-E6927426B8D9

P407

Q27652166-DB38D6AB-D727-4CD2-814F-AE59A870FD44

P433

Q27652166-168DC3FD-577E-4C2B-A8F8-1C5DEAD2E8AB

P478

Q27652166-8A4B3802-38AB-42B0-9849-F36D4A9B753E

P50

Q27652166-8F3462B3-A416-4362-867C-2F0584B2F3ED

Q27652166-C9743BBE-0FFF-4BE9-B728-7671E87CECFD

Q27652166-E67295C0-F21D-435E-B84D-7905ACFDA2AA

P577

Q27652166-2AD54F50-668A-4364-A121-0AD8D14C51E8

P5875

Q27652166-FD683DFB-FDFA-4A71-B815-8032E28297CC

P6179

Q27652166-96AF346F-93E1-4C3A-946E-359C108F0318

P698

Q27652166-BA4FBAA9-F950-4C4D-A9A9-990A97A72F83

P921

Q27652166-3A902DEF-1230-498A-95FB-7ACC03874688

P932

Q27652166-C236701F-A299-4862-9D80-1B6CD5B50196

P3181

P356

P1433

Nature Structural & Molecular Biology

P1476

Activation of tyrosine kinases by mutation of the gatekeeper threonine

@en

P2093

Mohammad Azam

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Structural basis for the autoinhibition of c-Abl tyrosine kinase

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty

Three-dimensional structure of the tyrosine kinase c-Src

Crystal structure of the Src family tyrosine kinase Hck

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P2888

P304

1109-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

204781

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NSMB.1486

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

George Q. Daley

Markus A Seeliger

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23258292

http://www.w3.org/2001/XMLSchema#string

P6179

1042536569

http://www.w3.org/2001/XMLSchema#string

P698

18794843

http://www.w3.org/2001/XMLSchema#string

P921

structural biology

P932

2575426

http://www.w3.org/2001/XMLSchema#string